Geode Capital Management LLC lessened its position in shares of Astrazeneca Plc (NYSE:AZN – Free Report) by 3.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 486,246 shares of the company’s stock after selling 17,227 shares during the quarter. Geode Capital Management LLC’s holdings in Astrazeneca were worth $85,336,000 as of its most recent SEC filing.
Several other large investors have also recently modified their holdings of the company. Coordinated Financial Services Inc. bought a new position in shares of Astrazeneca during the 4th quarter worth approximately $420,000. Fidelis Capital Partners LLC raised its stake in shares of Astrazeneca by 27.1% during the 4th quarter. Fidelis Capital Partners LLC now owns 4,998 shares of the company’s stock worth $877,000 after acquiring an additional 1,066 shares in the last quarter. King Luther Capital Management Corp raised its stake in shares of Astrazeneca by 2.6% during the 4th quarter. King Luther Capital Management Corp now owns 4,625 shares of the company’s stock worth $812,000 after acquiring an additional 118 shares in the last quarter. Banco de Sabadell S.A increased its stake in Astrazeneca by 22.4% during the 4th quarter. Banco de Sabadell S.A now owns 6,773 shares of the company’s stock valued at $1,189,000 after purchasing an additional 1,239 shares in the last quarter. Finally, Flputnam Investment Management Co. increased its stake in Astrazeneca by 3.7% during the 4th quarter. Flputnam Investment Management Co. now owns 335,558 shares of the company’s stock valued at $58,890,000 after purchasing an additional 12,056 shares in the last quarter. Institutional investors own 20.35% of the company’s stock.
Analyst Upgrades and Downgrades
A number of research analysts have issued reports on the stock. Wall Street Zen upgraded shares of Astrazeneca from a “hold” rating to a “buy” rating in a research note on Saturday, May 2nd. JPMorgan Chase & Co. restated a “buy” rating on shares of Astrazeneca in a research note on Monday, June 1st. TD Cowen restated a “buy” rating on shares of Astrazeneca in a research note on Wednesday, March 18th. UBS Group restated a “buy” rating on shares of Astrazeneca in a research note on Friday, April 10th. Finally, DZ Bank upgraded shares of Astrazeneca from a “neutral” rating to a “buy” rating in a research note on Wednesday, April 29th. Twelve investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $205.33.
Astrazeneca Stock Up 0.1%
AZN stock opened at $186.06 on Monday. The firm’s fifty day simple moving average is $190.84 and its 200-day simple moving average is $185.34. The company has a market capitalization of $288.57 billion, a P/E ratio of 27.94, a price-to-earnings-growth ratio of 1.59 and a beta of 0.25. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.91 and a quick ratio of 0.71. Astrazeneca Plc has a 12 month low of $137.23 and a 12 month high of $212.71.
Astrazeneca (NYSE:AZN – Get Free Report) last released its quarterly earnings data on Wednesday, April 29th. The company reported $2.58 EPS for the quarter, beating the consensus estimate of $2.52 by $0.06. The business had revenue of $15.29 billion for the quarter, compared to the consensus estimate of $14.93 billion. Astrazeneca had a net margin of 17.19% and a return on equity of 30.86%. As a group, equities research analysts forecast that Astrazeneca Plc will post 9.52 earnings per share for the current year.
About Astrazeneca
AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.
The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.
See Also
- Five stocks we like better than Astrazeneca
- These 3 Insurance Stocks Made New 52-Week Highs: Still Time to Buy?
- 3 Stocks Under $20 to Buy Before a Broader Market Rally
- Petco Faces Tough Competition, But Momentum Is Building
- The Lock-In Effect Is Real—These 3 Homebuilders Are Betting on It
Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Astrazeneca Plc (NYSE:AZN – Free Report).
Receive News & Ratings for Astrazeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca and related companies with MarketBeat.com's FREE daily email newsletter.
